• 2024
  Mejri H, Mokrani R, Ksouri A, Seddik M, Awad N, Ayme G, Chagour T, Mokrani A, Louchene CE, Salhi I, Ben Abderrazek R, Khalifa RB, Benlasfar Z, Corringer PJ, Hammadi M, Djilani S, Lafaye P, Bouhaouala-Zahar B, Neutralizing Nanobodies against Venoms from Naja haje Species Captured in North Africa., Toxins (Basel) 2024 Sep; 16(9): .
• 2024
  David Fernandez-Martinez, Youxin Kong, Sylvie Goussard, Agustin Zavala, Pauline Gastineau, Martial Jean-Pierre Rey, Gabriel Ayme, Julia Chamot‐rooke, Pierre Lafaye, Matthijn Vos, Ariel Mechaly, Guillaume Duménil, Cryo-EM structures of type IV pili complexed with nanobodies reveal immune escape mechanisms, Nature Communications, 2024, 15 (1), pp.2414. ⟨10.1038/s41467-024-46677-y⟩.
• 2023
  Prevost MS, Barilone N, Dejean de la Bâtie G, Pons S, Ayme G, England P, Gielen M, Bontems F, Pehau-Arnaudet G, Maskos U, Lafaye P, Corringer PJ, An original potentiating mechanism revealed by the cryo-EM structures of the human α7 nicotinic receptor in complex with nanobodies., Nat Commun 2023 Sep; 14(1): 5964.
• 2023
  Li Q, Nemecz Á, Aymé G, Dejean de la Bâtie G, Prevost MS, Pons S, Barilone N, Baachaoui R, Maskos U, Lafaye P, Corringer PJ, Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor., Cell Mol Life Sci 2023 May; 80(6): 164.
• 2023
  Cawez F, Mercuri PS, Morales-Yãnez FJ, Maalouf R, Vandevenne M, Kerff F, Guérin V, Mainil J, Thiry D, Saulmont M, Vanderplasschen A, Lafaye P, Aymé G, Bogaerts P, Dumoulin M, Galleni M. , Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases., Antimicrob Agents Chemother. .
• 2022
  Gransagne M, Aymé G, Brier S, Chauveau-Le Friec G, Meriaux V, Nowakowski M, Dejardin F, Levallois S, Dias de Melo G, Donati F, Prot M, Brûlé S, Raynal B, Bellalou J, Goncalves P, Montagutelli X, Di Santo JP, Lazarini F, England P, Petres S, Escriou N, Lafaye P, , Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein., J Biol Chem 2022 Jan; 298(1): 101290.
• 2020
  Barbon E, Ayme G, Mohamadi A, Ottavi JF, Kawecki C, Casari C, Verhenne S, Marmier S, van Wittenberghe L, Charles S, Collaud F, Denis CV, Christophe OD, Mingozzi F, Lenting PJ, , Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors., EMBO Mol Med 2020 Apr; 12(4): e11298.
• 2018
  Muczynski V, Casari C, Moreau F, Aymé G, Kawecki C, Legendre P, Proulle V, Christophe OD, Denis CV, Lenting PJ, , A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation., Blood 2018 Sep; 132(11): 1193-1197.
• 2018
  Wohner N, Muczynski V, Mohamadi A, Legendre P, Proulle V, Aymé G, Christophe OD, Lenting PJ, Denis CV, Casari C, , Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor., Haematologica 2018 Apr; 103(4): 728-737.
• 2017
  Aymé G, Adam F, Legendre P, Bazaa A, Proulle V, Denis CV, Christophe OD, Lenting PJ, , A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report., Arterioscler Thromb Vasc Biol 2017 Sep; 37(9): 1736-1740.
• 2017
  Muczynski V, Aymé G, Regnault V, Vasse M, Borgel D, Legendre P, Bazaa A, Harel A, Loubière C, Lenting PJ, Denis CV, Christophe OD, , Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions., Blood 2017 Apr; 129(17): 2443-2454.
• 2016
  Kauskot A, Poirault-Chassac S, Adam F, Muczynski V, Aymé G, Casari C, Bordet JC, Soukaseum C, Rothschild C, Proulle V, Pietrzyk-Nivau A, Berrou E, Christophe OD, Rosa JP, Lenting PJ, Bryckaert M, Denis CV, Baruch D, , LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B., JCI Insight 2016 Oct; 1(16): e88643.